SHR-3079 / Jiangsu Hengrui Pharma - LARVOL DELTA

A Clinical Study of SHR-3079 in B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1 | N=90 | Recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

A Clinical Study of SHR-3079 in B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - P1 | N=90 | Not yet recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

New P1 trial • B Cell Non-Hodgkin Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

HENGRUI PHARMA…announced that its subsidiary, Suzhou Suncadia Biopharmaceuticals, has received the Drug Clinical Trial Approval Notice for the SHR-3079 injection issued by the National Medical Products Administration, and will commence clinical trials in the near term. (iis.aastocks.com) - "SHR-3079 injection is an innovative anti-tumor drug independently developed by the company, and is intended for the treatment of B-cell non-Hodgkin lymphoma."

New trial • B Cell Non-Hodgkin Lymphoma